Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
TLDR
In this paper, the authors investigated the effect of GLP-1 receptor agonists on glycaemic control and weight loss in patients with Type 2 diabetes (T2D) using US electronic health records and prescription data.Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for glycaemic control and weight loss in patients with type 2 diabetes (T2D). In this retrospective, observational study, we analysed glycated haemoglobin (HbA1c) and weight following switching to semaglutide from any other GLP-1 RA, using US electronic health records and prescription data. Adults (≥ 18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index. HbA1c and weight cohorts were analysed separately using an ANCOVA model. Sensitivity analyses were conducted in patients with at least two prescriptions for pre-switch GLP-1 RA. A secondary analysis compared subgroups receiving different GLP-1 RAs pre-switch. Patients with HbA1c (n = 710) and weight (n = 921) data had similar baseline characteristics. Significant reductions in HbA1c at 6 months (0.7%; 95% confidence interval [CI] − 0.8, − 0.6) were sustained at 12 months. Weight reductions were significant at 6 months (− 2.1 kg; 95% CI − 2.6, − 1.6) and greater at 12 months (− 2.8 kg; 95% CI − 3.9, − 1.8). These patterns were consistent with the two-prescription sensitivity analysis and independent of the pre-switch GLP-1 RA. Switching to injectable semaglutide from any other GLP-1 RA was associated with significant improvements in glycaemic control and weight. Our findings support decision-making in clinical practice in patients with an indication to switch between GLP-1 RAs.read more
Citations
More filters
Journal ArticleDOI
Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
TL;DR: In this paper, the authors used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment-naive adult patients with type-2 diabetes (T2D) initiating semaglutide QW, dulaglanutide, liragluytide, and exenatide Qw between January 1, 2018 and April 30, 2019.
Journal ArticleDOI
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
TL;DR: In this article , the authors evaluated the effectiveness and safety of semaglutide in people with Type 2 diabetes (T2D) managed under routine care and found significant improvements in clinical outcomes from baseline to 6 and 12 months.
Journal ArticleDOI
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
Jean-François Yale,Ulrik Bodholdt,Andrei Mircea Catarig,Sergiu-Bogdan Catrina,A. Clark,Neda Rajamand Ekberg,Umut Erhan,Patrick Holmes,Søren Tang Knudsen,Joanne Liutkus,Thozhukat Sathyapalan,Bernd Schultes,Gottfried Rudofsky +12 more
TL;DR: In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA1c and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semag lutide, supporting OWSemaglUTide use in clinical practice.
Journal ArticleDOI
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Paolo Marzullo,Tommaso Daffara,Chiara Mele,Marco Zavattaro,Alice Ferrero,Marina Caputo,Flavia Prodam,Gianluca Aimaretti +7 more
TL;DR: In this paper , the authors explored the impact of semaglutide on biochemical and anthropometric outcomes after 6 and 12 months in patients receiving at least one prescription of OW semaglocortide between September 2019 and May 2021.
Journal ArticleDOI
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
TL;DR: In this article , the impact of semaglutide on metabolic control, cardiovascular risk, dietary behavior, and treatment satisfaction in T2DM patients was evaluated by a retrospective observational study conducted in a diabetes clinic.
References
More filters
Journal ArticleDOI
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
TL;DR: It is concluded that the adapted comorbidity index will be useful in studies of disease outcome and resource use employing administrative databases.
ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES
TL;DR: It is concluded that the adapted comorbidity index will be useful in studies of disease outcome and resource use employing administrative databases.
Journal ArticleDOI
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley,Vanita R. Aroda,Ildiko Lingvay,Jörg Lüdemann,Camilla Andreassen,Andrea Navarria,Adie Viljoen +6 more
TL;DR: This head-to-head trial compared semaglutide with dulag lutide in patients with inadequately controlled type 2 diabetes, finding that gastrointestinal disorders were the most frequently reported adverse event and bodyweight superiority was powered for HbA1c non-inferiority and body weight superiority.
Journal ArticleDOI
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial*
Andrew J. Ahmann,Matthew Capehorn,Guillaume Charpentier,Francesco Dotta,Elena Henkel,Ildiko Lingvay,Anders G. Holst,Miriam Annett,Vanita R. Aroda +8 more
TL;DR: Semaglutide 1.0mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles, indicating that semaglUTide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Journal ArticleDOI
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
Matthew Capehorn,A.-M. Catarig,J.K. Furberg,A. Janez,Hermione Price,S. Tadayon,B. Vergès,Michel Marre +7 more
TL;DR: SemagLutide was superior to liraglutide in reducing HbA1c and body weight and safety profiles were generally similar, except for higher rates of gastrointestinal AEs with semaglUTide vs liragsutide.
Related Papers (5)
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Gian Paolo Fadini,Veronica Sciannameo,I. Franzetti,Daniele Bottigliengo,Paola D'Angelo,Carmela Vinci,Paola Berchialla,Salvatore Arena,Raffaella Buzzetti,Angelo Avogaro,Agostino Consoli,Gloria Formoso,Giovanni Battista Grossi,A. Pucci,Giorgio Sesti,Francesco Andreozzi,G. Capobianco,A. Gatti,Riccardo C. Bonadonna,Ivana Zavaroni,A. D. Cas,G. Felace,P. L. Volsi,Gaetano Leto,G. P. Sorice,Susanna Morano,Antonio Bossi,E. Duratorre,Paola Silvia Morpurgo,Emanuela Orsi,F. Querci,Massimo Boemi,Federica D'Angelo,M. Petrelli,G. Aimaretti,I. Karamouzis,Franco Cavalot,G. Saglietti,G. Cazzetta,S. Cervone,E. Devangelio,Olga Lamacchia,A. Di Benedetto,Lucia Frittitta,Carla Giordano,Salvatore Piro,Manfredi Rizzo,Roberta Chianetta,Carlo Mannina,Roberto Anichini,Giuseppe Penno,Anna Solini,B. Fattor,Enzo Bonora,Massimo Cigolini,Annunziata Lapolla,Nino Cristiano Chilelli,M. Poli,Natalino Simioni,Vera Frison +59 more